Brind.
  1. Capricor Therapeutics is seeking FDA approval for its deramiocel cell therapy, with announcements made at biotech events and trading on the electronic stock exchange.

FDA documents challenged Capricor's claims while the company remains listed on Nasdaq.

5 reports, 2 independent Updated Aug 27
Gone quiet Reached 2 outlets in its first 24 hours
Reports
5
Developments
2
Repetition
60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

FDA documents challenged Capricor's claims while the company remains listed on Nasdaq.

Who's involved

What this event is mainly about
FDANasdaqcompany

How it developed

Newest first. Tap a step to see who reported it.
  1. Executive appointment and license negotiation details emerge regarding the company's operations in the Middle East.1 source
  2. FDA documents challenged Capricor's claims while the company remains listed on Nasdaq.1 source

Keep exploring

Part of

Capricor Therapeutics is seeking FDA approval for its deramiocel cell therapy, with announcements made at biotech events and trading on the electronic stock exchange. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story